News and Announcements
Shivom to feature in CNBC’s Advancements series following the Alpha public release
- Published December 03, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Shivom team are thrilled to launch their Alpha technology with the public.
- The company will feature in CNBC’s Advancements hosted by Ted Danson.
- Shivom’s CEO gave a keynote speech as the Digital Freedom Festival in Riga.
The Shivom team are excited to launch their Alpha with the public.
The team has been working tirelessly on the launch of the Alpha product which aims to showcase one of the companies USP’s – secure storage of DNA data.
The Alpha product enables individuals to control and access their genomic data.
Shivom will be featuring in CNBC’s Advancements hosted by Ted Danson. Advancements is an educational series dedicated to informing the public about the latest innovations taking place today.
Advancements explores the significant issues impacting society and aim to uncover the best kept secrets to raise social awareness.
Shivom’s feature on the programme will take place on Sunday December 16th and will bring further awareness to the Shivom brand and their tech innovations.
Shivom’s CEO, Henry Ines gave a keynote speech at the Digital Freedom Festival in Riga, Latvia last week.
The festival unites the world of technology and encourages debate on how technologies can make the world a better place.
Henry gave a keynote speech titled “The Future of Health: Reinvention of Healthcare & Wellness” and launched their Alpha public release at the event.
Upcoming Events for Shivom
- Genesis 2018 – Dec 12 to Dec 13
- PMWC 2018 – Dec 23 to Jan 21
- Bockchain Applications for Pharma – Jan 23 to Jan 24
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
